The Oncology Newsletter is published every week and is distributed to oncology healthcare professionals with a tightly curated roundup of the week’s news highlights, including headlines from national and international sources, updates that have been overlooked by mainstream media, and expert commentary pieces.
It’s also home to The Oncology Journal Club which produces a weekly podcast hosted by Eva Segalov, Craig Underhill and Hans Prenen where they chat through the latest papers and pretty much solve many of the world’s ills in addition to their big, day-jobs in cancer.
The first episode of The Oncology Podcast went to air in May 2020. Rachael Babin, Editor-in-Chief, Oncology News says they are aiming to deliver oncology news differently, taking an old concept and updating it into a new format. In each episode a team of expert contributors review topical journal papers and studies presented at key meetings to keep you informed of the latest developments on the go.
Now the team is up to Episode 54 and they’ve well and truly earned their chops as broadcasters. In this week’s episode Eva talks listeners through tumour burden and efficacy of immune-checkpoint inhibitor. Hans gets stuck into aligning tumour mutational burden quantification across diagnostic platforms and Craig details the CheckMate 142 Study. You’ll find out how to deliver Cancer Care in the Wake of a Cyberattack (hands up all the subject matter experts on that one), and apparently coffee is still good for you.
In addition to weekly episodes, there is also the special ‘The OJC Meets…’ series in which listeners spend time with leaders in the cancer field, often sharing in surprising revelations and insights. Recently Eva spoke to Professor Nathan Cherny, who leads the Multidisciplinary Cancer Pain and Palliative Medicine Service at Shaare Zekek Medical Center, in Jerusalem, Israel and is the mastermind behind the ESMO Magnitude of Clinical Benefit Scale.
In early December, Nathan will be a guest of the VCCC Alliance for meetings and a seminar, Taking off the rose coloured glasses - and the peril if we don’t, where he will explore how to critically evaluate clinical research studies and trials for impact. Details will be on the VCCC Alliance events page very soon.
Image: Professor Nathan Cherny
